• 19 March 2015
    Creabilis’ CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board

    Creabilis Ltd, the dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch), announces today that it has published positive Phase 2b clinical data for its novel TrkA kinase inhibitor CT327 in Acta Dermato-Venereologica, one of the pre-eminent international peer-review journals in dermatology.

    The paper outlines the data reported with the Company’s lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itch) due to psoriasis, a condition where there is no approved standard of care currently. In the multinational randomized, double-blind, vehicle-controlled Phase 2b trial, clinically and statistically-significant reductions (p=0.0067) in pruritus were seen in patients with mild to moderate pruritus treated with CT327.

    This builds on previous work published by Creabilis in the Journal of the American Academy of Dermatology , which demonstrates a lack of correlation between psoriasis disease severity and pruritus severity, highlighting the need for targeted anti-pruritic treatments for patients with psoriasis and other dermatological conditions.

    Creabilis also announced today the strengthening of its Scientific Advisory Board (SAB) to prepare it for Phase 3 development of CT327. Professor Gil Yosipovitch, Chair of the Department of Dermatology at the Temple University School of Medicine, Director of the Temple Center for Itch and one of the world’s pre-eminent experts in itch, has been appointed Chair of the SAB. In addition, Professor Sonja Ständer, Professor for Dermatology and Neurodermatology at the Department of Dermatology, and Head of the Interdisciplinary Competence Center Chronic Pruritus (KCP) of the University Hospital Münster, Germany, joins as a new SAB member.

    Professor Yosipovitch commented: “I am excited to be leading Creabilis’ Scientific Advisory Board at this important time in CT327’s development. Chronic Pruritus has a significant impact on the quality of life of patients with psoriasis and there is a clear unmet medical need for a safe, effective topical anti-pruritic. Based on the robust data from the Phase 2b trial, now reported in the prestigious dermatology journalActa Dermato-Venereologica, I believe that CT327 could have a significant impact in the treatment of pruritic conditions such as pruritus due to psoriasis and offers broad development opportunities in the future to address other pruritic indications.”